Cargando…

Efficacy and Safety of First-Line Chemotherapies for Patients With Advanced Biliary Tract Carcinoma: A Systematic Review and Network Meta-Analysis

BACKGROUND: At present, chemotherapy is still the primary treatment for advanced biliary tract carcinoma, but it is challenging to balance the efficacy and side effects. Network meta-analysis (NMA) is a better way to identify the protocol, and the advantage is that it can be combined with direct and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Yanfeng, Zeng, Zhiming, Zeng, Jie, Liu, Cuizhen, Qiu, Jinfeng, Li, Ye, Tang, Jing, Mo, Ning, Du, Lihua, Ma, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507323/ https://www.ncbi.nlm.nih.gov/pubmed/34650920 http://dx.doi.org/10.3389/fonc.2021.736113

Ejemplares similares

A retrospective cohort study on the efficacy and safety for combination therapy of immunotherapy, targeted agent, and chemotherapy versus immunochemotherapy or chemotherapy alone in the first-line treatment of advanced biliary tract carcinoma
por: Zeng, Jie, et al.
Publicado: (2023)

Lenvatinib Beyond First-Line Therapy in Patients With Advanced Biliary Tract Carcinoma
por: Wang, Yunchao, et al.
Publicado: (2022)

The Efficacy and Safety of First-line Chemotherapies for Advanced Biliary Tract Cancer: A Network Meta-analysis
por: Zheng, Wei, et al.
Publicado: (2019)

PD-1 Inhibitors Could Improve the Efficacy of Chemotherapy as First-Line Treatment in Biliary Tract Cancers: A Propensity Score Matching Based Analysis
por: Gou, Miaomiao, et al.
Publicado: (2021)

Cost-effectiveness analysis of durvalumab plus chemotherapy as first-line treatment for biliary tract cancer
por: Ye, Zhuo-miao, et al.
Publicado: (2023)

The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study
por: Wang, Dongxu, et al.
Publicado: (2021)

Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy
por: Fiteni, Frédéric, et al.
Publicado: (2014)

The Efficacy of Different Chemotherapy Regimens for Advanced Biliary Tract Cancer: A Systematic Review and Network Meta-Analysis
por: Li, Yan, et al.
Publicado: (2019)

Safety and Effectiveness of Chemotherapy in Elderly Biliary Tract Cancer Patients
por: Okamoto, Takeshi, et al.
Publicado: (2023)

Investigation of chemoresistance to first-line chemotherapy and its possible association with autophagy in high-risk neuroblastoma
por: Chen, Tingting, et al.
Publicado: (2022)

Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study
por: Zhang, Qiyi, et al.
Publicado: (2021)

Oligorecurrence Non–small Cell Lung Cancer After Failure of First-Line Chemotherapy: Computed Tomography–Guided (125)I Seed Implantation vs. Second-Line Chemotherapy
por: Wang, Hao, et al.
Publicado: (2020)

Biliary Tract Carcinogenesis Model Based on Bile Metaproteomics
por: Arteta, Ariel A., et al.
Publicado: (2020)

First Line and Second Line Chemotherapy in Advanced Cholangiocarcinoma and Impact of Dose Reduction of Chemotherapy: A Retrospective Analysis
por: Möhring, Christian, et al.
Publicado: (2021)

Safety and efficacy of GEMOX plus donafenib and tislelizumab as first‐line therapy for advanced epithelial malignant biliary tract cancer
por: Wang, Longrong, et al.
Publicado: (2023)

Metformin and Biliary Tract Cancer in Patients With Type 2 Diabetes
por: Tseng, Chin-Hsiao
Publicado: (2020)

Prognostic Significance of Sarcopenia in Advanced Biliary Tract Cancer Patients
por: Lee, Byung min, et al.
Publicado: (2020)

The Evolving Role of Radiation Therapy in the Treatment of Biliary Tract Cancer
por: Gkika, Eleni, et al.
Publicado: (2020)

Case Report: Trastuzumab Treatment in Adenosquamous Carcinoma of the Extrahepatic Biliary Tract With Her-2 Amplification
por: Hong, Ye, et al.
Publicado: (2021)

Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trial
por: Zhao, Qiuling, et al.
Publicado: (2023)

Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer
por: Zeng, Tian-mei, et al.
Publicado: (2023)

Quality of life across chemotherapy lines in patients with cancers of the pancreas and biliary tract
por: Zabernigg, August, et al.
Publicado: (2012)

Chemotherapy for Biliary Tract Cancer in 2021
por: Sasaki, Takashi, et al.
Publicado: (2021)

PD-1 inhibitor versus bevacizumab in combination with platinum-based chemotherapy for first-line treatment of advanced lung adenocarcinoma: A retrospective-real world study
por: Huang, Zhe, et al.
Publicado: (2022)

A retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancer
por: Ulusakarya, Ayhan, et al.
Publicado: (2020)

Presentation and Outcomes with First-Line Chemotherapy in Advanced Cholangiocarcinomas—A Relatively Rare Component of Biliary Tract Cancers in India
por: Bhargava, Prabhat G., et al.
Publicado: (2020)

High Response Rate and Prolonged Survival of Unresectable Biliary Tract Cancer Treated With a New Combination Therapy Consisting of Intraarterial Chemotherapy Plus Radiotherapy
por: Goto, Takuma, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
por: Hu, Huabin, et al.
Publicado: (2020)

Predictive value of DNA methylation in the efficacy of chemotherapy for gastric cancer
por: Li, Ye, et al.
Publicado: (2023)

Cost-effectiveness analysis of pembrolizumab in combination with chemotherapy compared with chemotherapy alone as first-line treatment for patients with advanced biliary tract cancer in China
por: Zheng, Zhiwei, et al.
Publicado: (2023)

Immune checkpoint inhibitors plus capecitabine and oxaliplatin in unresectable or advanced biliary tract cancer patients: A retrospective study
por: Zhao, Jie, et al.
Publicado: (2022)

Adjuvant Therapy for Resectable Biliary Tract Cancer: A Bayesian Network Analysis
por: Chen, Xiuqiong, et al.
Publicado: (2021)

HER2 Aberrations as a Novel Marker in Advanced Biliary Tract Cancer
por: Kim, Hongsik, et al.
Publicado: (2022)

Comprehensive germline and somatic genomic profiles of Chinese patients with biliary tract cancer
por: Yu, Haipeng, et al.
Publicado: (2022)

Immune checkpoint inhibitors alone or in combination with chemotherapy for treatment of advanced non-small cell lung cancer after first-line platinum-based chemotherapy: A propensity score matching analysis
por: Qiu, Lupeng, et al.
Publicado: (2022)

Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer
por: Fornaro, L, et al.
Publicado: (2014)

Economic evaluation of first-line sugemalimab plus chemotherapy for metastatic non-small cell lung cancer in China
por: Wang, Hao, et al.
Publicado: (2022)

The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy
por: Faloppi, Luca, et al.
Publicado: (2016)

Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy
por: Suzuki, Yuko, et al.
Publicado: (2018)

Guidelines for chemotherapy of biliary tract and ampullary carcinomas
por: Furuse, Junji, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_32496igo47dh52p0gun7p8a1gg